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Efficacy and tolerability of lercanidipine 
in mild to moderate hypertension among 
Asians of different ethnic groups
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ABSTRACT
Introduction: Calcium channel blockers are 
well established modalities for the treatment of 
hypertension. However, in spite of the availability 
of many efficacious agents, hypertension control 
continues to be poor. One reason is poor tolerability 
due to adverse events. Racial differences also exist. 
Lercanidipine, a third-generation calcium channel 
blocker, is associated with better tolerability. 
However, it has not been studied in the Asian 
population. This study examines its efficacy 
and tolerability in Asian subjects of different 
ethnicities.
Methods: This was an eight-week open label study 
of adults with mild to moderate hypertension. 
Blood pressure (BP), pulse rate, self-administered 
symptom check and laboratory evaluations were 
done at baseline. Patients were prescribed 10 mg 
lercanidipine, with up-titration to 20 mg if BP was 
not controlled at Week 4. Baseline evaluations 
were repeated at Week 8. Adverse events were 
also enumerated.
Results: 27 patients (mean age 53.4 +/− 12.1 
years) completed the study. The baseline systolic 
BP (SBP), diastolic BP (DBP) and heart rate 
was 159 +/− 12.2, 96.6 +/− 7.7 mmHg and 71 +/− 
13/min, respectively. Three racial groups were 
represented. SBP and DBP decreased significantly 
after four weeks of therapy. A further reduction 
to 139 +/− 14.3 and 88 +/− 9.8 (p-value is less than 
0.0001) was seen in Week 8. The absolute SBP 
and DBP reduction was 20.5 mmHg (95 percent 
confidence interval [CI] 16.5–24.5, p-value is less 
than 0.0001) and 9.3 mmHg (95 percent CI 6.2–
12.5,  p-value is less than 0.0001), respectively. All 
adverse symptoms, except for palpitations, were 
reduced at the end of the study.
Conclusion: Lercanidipine is efficacious and well 
tolerated in Asians of different ethnicities. Its BP 
lowering effects and tolerability in Asians appear 
to be similar to other studies on Caucasians and 
other calcium channel blockers.
Keywords: blood pressure, calcium channel 
blockers, hypertension, lercanidipine
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INTRODuCTION
A lowering of just 12 mmHg systolic blood pressure (SBP) 
in hypertensive patients reduces heart failure by 50%, 
stroke by 48% and coronary heart disease by a more modest 
16%.(1,2) Calcium channel blockers (CCBs) have been widely 
used for the treatment of systemic arterial hypertension for 
more than 20 years.(3) All the drugs in this class have been 
shown to be effective in lowering BP and cardiovascular 
events in hypertensive patients, either as monotherapy or 
in combination with other drug classes.(4-8)  In particular, 
dihydropyridine (DHP) CCBs have been shown to reduce 
cardiovascular events in older patients with isolated systolic 
hypertension.(4,9) Furthermore, DHP CCBs have been shown 
in a randomised, placebo-controlled, crossover study to be 
more effective than angiotensin-coverting enzyme (ACE) 
inhibitors or β-blockers in lowering SBP in 65- to 86-year-
old patients with hypertension.(10) With the availability 
of so many classes of antihypertensives that are effective 
in lowering BP as well as in reducing cardiovascular 
events,(5-8,11) it might well be asked why hypertension is 
not better controlled. The cause of this is complex and 
multifactorial, but the two most likely reasons are using too 
few drugs to achieve the goal BP and poor drug tolerability. 
Poor drug tolerability in turn promotes poor adherence to 
therapy and it is well documented that one in four patients 
discontinue antihypertensive treatment within the first year 
of therapy because of adverse events.(12-14)
 Many antihypertensive medications display 
characteristic class-wide adverse events but even within 
a class, the DHP CCBs included, there are fundamental 
differences between them.(15) The development of newer 
generations of DHP CCBs from the prototype (nifedipine) 
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usually endows them with different pharmacokinetics 
and consequently perhaps a better safety and tolerability 
profile. However, most of the studies on the efficacy and 
tolerability of antihypertensives, including CCBs, have 
been done on a mainly western population.  Most adverse 
events are dose-related, but even for those classes of 
antihypertensive agents whose adverse events are not dose-
related, e.g. the ACE inhibitors, the frequency of cough 
associated with ACE inhibitors varies among different 
populations and is much higher than expected in Asians 
compared to the Caucasian population.(16-18)
 Lercanidipine is a third-generation DHP CCB that 
is lipophilic. It is characterised by a gradual onset and 
long duration of action, as well as vascular selectivity 
and a lack of inotropic effects.  It is effective in different 
types of arterial hypertension and its therapeutic efficacy 
is similar to other DHP CCBs. Lercanidipine has been 
shown to be well-tolerated and its adverse events lower 
than other commonly-used DHP CCBs in Caucasian 
hypertensive patients.(19-21) As efficacy and tolerability 
to antihypertensives may vary between populations, this 
study was done to examine the efficacy and tolerability of 
lercadinipine in Asians.
METHODS
This was an investigator-initiated study. At the time this 
study was conducted, lercanidipine was not yet registered 
for use in the country. It was a prospective, open-label trial 
in patients with mild to moderate hypertension. The study 
protocol design and data handling were all done by the 
investigators themselves. Informed consent was obtained 
from the patients and ethics approval from the institution 
was granted for this study.
 Adults with newly-diagnosed hypertension (140 ≤ 
SBP ≤  179 mmHg  and/or 90 ≤ diastolic BP [DBP] ≤ 109 
mmHg) or whose BP was not controlled on their current 
medication, were eligible to enter the study. Patients were 
excluded if there was evidence of recent (i.e. within the past 
six months) myocardial infarction, angioplasty, cardiac 
bypass surgery, unstable angina, cerebrovascular events, 
congestive heart failure (New York Heart Association 
Classes III and IV), clinically significant arrhythmia, liver 
or renal impairment, pregnancy, secondary hypertension 
or a known allergy to CCBs. As the predicted efficacy of 
lercanidipine is a SBP lowering of at least 10 mmHg with 
a 10-mg dose, to show a significant (p < 0.05) BP lowering 
between baseline and at the end of  four and eight weeks and 
with a 80% power to detect this difference, only 30 patients 
were required for this study. The data was analysed with 
an intention-to-treat basis using the Statistical Package for 
Social Sciences version 11.5 (SPSS Inc, Chicago, IL, USA) 
and the two-tailed paired sample t-test for the baseline and 
treatment period BP changes.
 This was an eight-week active treatment study.  Fig. 1 
shows the flow chart of the study design. At the screening 
visit (Visit 1, Week −2), sitting BP, physical examination, 
standard laboratory evaluations (complete blood count, 
urinalysis, fasting plasma glucose, serum lipids, blood 
urea nitrogen, serum creatinine, serum electrolytes, 
liver function tests), a 12-lead electrocardiogram (ECG) 
and chest radiography were done. After a two week run-
in or washout period (Visit 2, Week 0), the sitting BP 
was rechecked. At every visit, BP was recorded using a 
standardised mercury sphygmomanometer and the values 
were recorded as a mean of two measurements taken five 
minutes apart after a ten-minute rest. The patient was 
instructed to omit the medication dose on the morning 
of each study visit and SBP, DBP and heart rate (HR) 
were measured in the morning between 8 am and 12 pm. 
A review was done to ensure eligibility for the study. A 
Fig. 1 Flow chart of the study design.
* Titration was encouraged if SBP ≥ 140 mmHg or DBP  ≥ 90 mmHg. 
Run-in/wash out  Lercanidipine 20 mg*
Visit 1(Week −2) Visit 2 (Week 0)
•  Physical exam
•  Lab tests
•  ECG
•  Chest 
 radiograph
•  Informed
 consent
•  BP & HR
•  Recheck
 inclusion/exclusion
 criteria
• Symptom checklist
•  BP & HR
•  Adverse events
• Compliance
• Symptom checklist
• Dose titration, if any
•  BP & HR
•  Adverse events
• Compliance
• Symptom checklist
• Lab test/ECG
➞
➞ ➞ ➞➞
Lercanidipine 10 mg
Visit 3 (Week 4) Visit 4 (Week 8)
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self-administered symptom checklist was given to the 
patient at this point. The symptom checklist included all 
the documented adverse events associated with CCB usage 
and was applied at every subsequent visit. The patient was 
then started on 10 mg of lercanidipine and was seen four 
weeks later.
 At the third visit (Week 4), BP and HR were re-
measured. Besides applying the symptom checklist again, 
adverse events were also looked for by the investigators. 
Compliance was checked by a pill count. If the BP was not 
controlled, i.e. SBP  ≥ 140 and/or DBP  ≥ 90 mmHg, the 
dose of lercanidipine was titrated to 20 mg and the patient 
was seen another four weeks later. At the last visit (Visit 
4, Week 8), BP, HR, adverse events, pill count and the 
symptom checklist were done again. The laboratory test 
and ECG were repeated during this last visit. Efficacy is 
defined as a BP-lowering effect of at least 10/5 mmHg and 
tolerability as not needing to go off treatment because of 
adverse events related to the drug. 
RESuLTS
30 patients were entered into the trial. 27 completed the 
study. One patient voluntarily withdrew from the study 
before the end of four weeks as she wanted to get her own 
medication from a clinic near her home. Another patient 
developed diarrhoea and while the clinical decision was 
made that she could continue with the study, the patient 
decided to withdraw from it. The third patient went for an 
unscheduled (but not emergency) herniorrhaphy. While 
he could not continue with the study, he was continued 
on the medication as the anaesthetist deemed the BP to 
be very well controlled, and was hence a very good and 
low surgical risk patient. The baseline characteristics 
are shown in Table I. The baseline mean of the SBP, 
DBP and HR was, respectively, 159 ± 12.2 mmHg, 96.6 
± 7.7 mmHg and 71 ± 13 min−1. 43.3% (13 out of 30) of 
the subjects had stage 1 hypertension and 56.7% (17 out 
of 30) had stage 2 hypertension.  Both genders and the 
three main racial groups were represented. The baseline 
biochemical parameters were unremarkable. Fig. 2 shows 
the BP changes at Week 4 and Week 8. The SBP and DBP 
values decreased significantly to 142 ± 15.1 and 87 ± 8.3 
mmHg, respectively, after four weeks of therapy. A further 
reduction was seen at the end of the study and actually 
achieved the goal of BP treatment, being 139 ± 14.3 and 
88 ± 9.8 mmHg, respectively.  Fig. 3 shows the absolute 
reduction in the mean SBP and DBP at the end of Week 4 
and Week 8. The mean SBP reduction was, respectively, 
Table I. Baseline characteristics of patients.
Demographics                      No. (%) of patients (n = 27)
                                        or mean ± SD of values
Gender
 Male                                             12 (42.3)
 Female                                          15 (57.7)
Race
 Chinese                                          12 (44.4)
 Malays                                             6 (22.2)
 Indians                                               9 (33.3)
Hypertension category
 Stage 1                                         13 (43.3)
 Stage 2                                           17 (56.7)
Age (years)                                            53.4 ± 12.1
Blood pressure (mmHg)
 Systolic                                          159.0 ± 12.2
 Diastolic                                          96.6 ± 7.7
Baseline readings (mmol/L)
 Glucose                                             5.8 ± 1.2
 Cholesterol                                        5.4 ± 1.1
 Triglycerides                                     1.7 ± 0.8
 Uric acid                                          330.8 ± 95.2
SD: standard deviation
Fig. 2 Bar chart shows the systolic and diastolic blood pressures 
at baseline, Week 4 and Week 8.
*p < 0.0001
Fig. 3 Bar chart shows the mean systolic and diastolic blood 
pressure reductions at Week 4 and Week 8.
*p < 0.0001
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16.8 (95% CI 12.8–20.8, p < 0.0001) and 20.5 (95% CI 
16.5–24.5, p < 0.0001) mmHg at Week 4 and Week 8 
compared to the baseline, and the mean DBP reduction 
was, respectively, 9.2 (95% CI 5.6–12.9, p < 0.0001) and 
9.3 mmHg (95% CI 6.2–12.5, p < 0.0001) at Week 4 and 
Week 8 compared to the baseline. Hence, it can be seen 
that lercanidipine is efficacious as it lowered the BP by 
more than 10/5 mmHg. Fig. 4 shows the response of the 
patients at the end of the study. The number of normalised 
patients (defined as BP < 140/90 mmHg) at the end of the 
study was 61.5% and 23.5% for those with stage 1 and 
stage 2 hypertension, respectively. Responders (defined 
as patients with DBP < 90 mmHg or with a reduction of 
DBP > 10 mmHg compared to the baseline) was 30.8% and 
47.1% for stage 1 and stage 2 hypertension, respectively. 
The remaining 7.7% and 29.4% with stage 1 and stage 2 
hypertension, respectively, did not normalise or respond. 
The three subjects who did not complete the study were 
included as non-responders as this was an intention-to-
treat analysis. There was no significant difference between 
the findings of the per-protocol and intention-to-treat 
analysis. Compliance done by pill count was very good, 
with all patients who completed the study achieving more 
than 80%. No deaths or other serious adverse events were 
encountered in this study. One patient voluntarily withdrew 
from the study because of diarrhoea although the clinical 
assessment was that she could have continued with the 
study at no increased risk. 
 There were no significant changes in the HR at the end 
of the study compared to the baseline, 72.2 vs. 72.9 min-1(p 
= 0.8), respectively. There were also no significant changes 
in the relevant metabolic parameters. No other clinically 
meaningful changes were noted at the end of the study. 
Furthermore, no clinically-significant abnormalities were 
seen in the ECG. Fig. 5 shows the frequency of symptoms 
at the baseline and at the end of the study. It can be seen 
that all symptoms were lessened at the end of the study 
compared to at baseline, except for palpitations, which 
occurred in two patients whose dose of lercanidipine was 
titrated to 20 mg for better BP control.
DISCuSSION
The results of this study confirm that lercanidipine 
is effective in lowering BP in the Asian population, 
and is similar to findings in other studies involving 
Caucasians.(21,22) Furthermore, the amount of BP lowering 
seen in this study is similar to that seen in other studies 
done in western countries and is also comparable to other 
commonly-used CCBs.(23- 25) That more than half of the 
patients with stage 1 hypertension had their BP normalised 
and achieved the target BP goals suggests that lercanidipine 
plays a big role as monotherapy in patients with stage 1 
hypertension.(21)  It is also known that some patients do 
not respond to certain classes of antihypertensive agents. 
Again, as seen here, of those who did not normalise their 
BP, 30.8% and 47.1% with stage 1 and stage 2 hypertension, 
respectively, responded to lercanidipine. This suggests 
that a second drug could be added in combination with 
lercanidipine to try to achieve the target BP.
 It is acknowledged that because this was not a blinded, 
randomised, controlled study (RCT) with a comparator or a 
placebo (placebo trials in hypertension are no longer allowed 
by ethics committees), the magnitude of BP lowering 
achieved in this study may be exaggerated. In earlier studies 
where placebo-controlled trials with active agents were 
allowed, the BP lowering achieved with placebo was SBP 
10–15 mmHg and DBP 2–5 mmHg.(2,4,9,26,27) On the other 
hand, the active agents achieved an SBP and DBP lowering 
of 20–27 mmHg and 5–8 mmHg, respectively. So while this 
study does not have a comparator nor is it compared against 
a placebo, the BP lowering achieved is well within these 
ranges. Discounting for the placebo effect, the “true” BP 
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Fig. 5 Bar chart shows the comparison of adverse events at 
baseline and at the end of the study.
Fig. 4 Bar chart shows the response after eight weeks of 
therapy.
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lowering of lercanidipine in this study can be estimated to be 
around 10/5 mmHg. This “true” BP lowering of around 10/5 
mmHg is also comparable to the magnitude of BP lowering 
in other studies where lercanidipine was compared in RCT 
to other agents.(21,23,25) 
 In terms of safety and tolerability, the symptoms 
and adverse events, except for palpitations, were low. In 
fact, the incidence of symptoms and adverse events was 
actually lower when patients were on lercanidipine. The 
incidence of these adverse symptoms is also similar to that 
seen in the western population,(24) again suggesting, unlike 
what was seen with ACE inhibitors, that lercanidipine is 
well tolerated by Asian patients. While this study has no 
comparator, in other studies that compared lercanidipine 
against other CCBs, the incidence of adverse events was 
lower in the lercanidipine group.(13,25,28)  Common adverse 
events like ankle oedema,(29,30)  headache and flushing 
appear to be much less common with lercanidipine than 
with the use of other DHP CCBs.(23,25,28)  This better profile 
of tolerability seen with lercanidipine can potentially 
enhance hypertension treatment by promoting better 
adherence to drug therapy.
 While there are currently no outcome studies to 
demonstrate a cardiovascular benefit through the use of 
lercanidipine in the treatment of hypertension, the very 
fact is that lercanidipine, just by its ability to lower BP 
effectively, may be translated into a potential benefit. 
Some CCBs that have been widely used in hypertensive 
patients for a good number of years did not initially 
have outcome studies either, but they also demonstrated 
BP lowering, and were subsequently shown to reduce 
cardiovascular morbidity and mortality.(5,6,8) Because it is of 
no advantage if a drug is efficacious but not well tolerated, 
lercanidipine, with its good safety and tolerability profile 
and its effectiveness in lowering BP, has a useful and 
important role to play in the treatment of mild to moderate 
hypertension(31,32) in Asians.
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